Online inquiry

IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14904MR)

This product GTTS-WQ14904MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets stx2 A-subunit gene. The antibody can be applied in hemolytic-uremic syndrome (HUS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq WP_001367518.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID Q8VLD2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14904MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4811MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ12281MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ6883MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ8195MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ15145MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ11579MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ7450MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ14467MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO-7105705
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW